Methylphenidate-oxoacid conjugates, processes of making and using the same
View Patent ↗The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.
1. A prodrug composition comprising at least one conjugate of methylphenidate wherein the conjugate is of the following structure:
wherein G 2 is selected from the group consisting of standard amino acids, nonstandard amino acids and synthetic amino acids; and
wherein the amino acid is attached to the rest of the molecule by an amide linkage.
2. The prodrug composition of claim 1 , wherein the amino acid is threonine.
3. The prodrug composition of claim 1 , wherein the amino acid is serine.
4. The prodrug composition of claim 1 , wherein the prodrug of methylphenidate has one of the following structures:
5. The prodrug composition of claim 1 , wherein the conjugate is a pharmaceutically acceptable anionic, amphoteric, zwitterionic or cationic salt form or salt mixtures thereof.
6. The prodrug composition of claim 5 , wherein the anionic salt form is selected from the group consisting of acetate, l-aspartate, besylate, bicarbonate, carbonate, d-camsylate, l-camsylate, citrate, edisylate, formate, fumarate, gluconate, hydrobromide/bromide, hydrochloride/chloride, d-lactate, l-lactate, d,l-lactate, d,l-malate, l-malate, mesylate, pamoate, phosphate, succinate, sulfate, bisulfate, d-tartrate, Martrate, d,l-tartrate, meso-tartrate, benzoate, gluceptate, d-glucuronate, hybenzate, isethionate, malonate, methylsufate, 2-napsylate, nicotinate, nitrate, orotate, stearate, tosylate, thiocyanate, acefyllinate, aceturate, aminosalicylate, ascorbate, borate, butyrate, camphorate, camphocarbonate, decanoate, hexanoate, cholate, cypionate, dichloroacetate, edentate, ethyl sulfate, furate, fusidate, galactarate (mucate), galacturonate, gallate, gentisate, glutamate, glutamate, glutarate, glycerophosphate, heptanoate (enanthate), hydroxybenzoate, hippurate, phenylpropionate, iodide, xinafoate, lactobionate, laurate, maleate, mandelate, methanesufonate, myristate, napadisilate, oleate, oxalate, palmitate, picrate, pivalate, propionate, pyrophosphate, salicylate, salicylsulfate, sulfosalicylate, tannate, terephthalate, thiosalicylate, tribrophenate, valerate, valproate, adipate, 4-acetamidobenzoate, camsylate, octanoate, estolate, esylate, glycolate, thiocyanate, and undecylenate.
7. The prodrug composition of claim 5 , wherein the anionic salt form is selected from the group consisting of sodium, potassium, calcium, magnesium, zinc, aluminium, lithium, cholinate, lysinium, ammonium and tromethamine.
8. The prodrug composition of claim 1 , wherein the composition is in the form comprising a tablet, a capsule, a caplet, a troche, a lozenge, an oral powder, a solution, a thin strip, an oral thin film (OTF), an oral strip, a rectal film, a transdermal patch, a syrup, a suspension, an inhalation compound or a suppository.
9. The prodrug composition of claim 1 , wherein the conjugate is of the following structure:
wherein G 2 is selected from the group consisting of standard amino acids, nonstandard amino acids and synthetic amino acids; and
wherein the amino acid is attached to the rest of the molecule by an amide linkage.